← Leaderboards
Frank A Sinicrope
University Of Texas Md Anderson Can Ctr
$7,695,451
Attributed
$7,695,451
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $880.5K · FY2005–21$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$7,695,451 · 6
By mechanism
R01$6,387,674 · 4
K05$807,777 · 1
N01$500,000 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Md Anderson Can Ctr
Same institution · by research overlap
- Robert C Bast$38,086,401
- Scott M Lippman$54,535,308
- Sanjay Shete$6,110,105
- Patricia Ann Thompson-Carino$8,608,763
- Jian Gu$3,482,931
Others in their field
Top investigators on “Colon Carcinoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$175,335,637
- Norman Wolmark · Nsabp Foundation, Inc.$48,722,384
- Robert J Coffey · Vanderbilt University$27,051,989
- Sanford D Markowitz · Case Western Reserve University$24,708,814
- Judith A James · Oklahoma Medical Research Foundation$20,921,391
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$20,805,164
Research focus
Colon CarcinomaRecurrenceMalignant NeoplasmsChemopreventionCancer PreventionFollow-UpResourcesColorectalApoptoticPathway InteractionsStagingBaseResearch PersonnelColorectal CancerColorectal NeoplasmsBiomarkerApoptosisPreventPlacebosMolecularMolecular TargetEventFutureHigh Risk
Grant awards (25)
Integration of Genomic and Clinical Data to Enhance Subtyping of Colon Cancer$407,754
R01 · FY2021 · CA · contact PI
Integration of Genomic and Clinical Data to Enhance Subtyping of Colon Cancer$413,430
R01 · FY2020 · CA · contact PI
Integration of Genomic and Clinical Data to Enhance Subtyping of Colon Cancer$394,948
R01 · FY2019 · CA · contact PI
Integration of Genomic and Clinical Data to Enhance Subtyping of Colon Cancer$381,129
R01 · FY2018 · CA · contact PI
Integration of Genomic and Clinical Data to Enhance Subtyping of Colon Cancer$376,745
R01 · FY2017 · CA · contact PI
Translational Research in Colon Cancer Prevention & Treatment$162,001
K05 · FY2013 · CA · contact PI
Polyphenon E for the Chemoprevention of Colorectal Cancer$1
R01 · FY2013 · CA · contact PI
Polyphenon E for the Chemoprevention of Colorectal Cancer$586,633
R01 · FY2012 · CA · contact PI
Translational Research in Colon Cancer Prevention & Treatment$162,001
K05 · FY2012 · CA · contact PI
Translational Research in Colon Cancer Prevention & Treatment$162,001
K05 · FY2011 · CA · contact PI
Polyphenon E for the Chemoprevention of Colorectal Cancer$1
R01 · FY2011 · CA · contact PI
Polyphenon E for the Chemoprevention of Colorectal Cancer$470,794
R01 · FY2010 · CA · contact PI
Translational Research in Colon Cancer Prevention & Treatment$162,001
K05 · FY2010 · CA · contact PI
Aberrant Crypt Foci as a Biomarker for Chemoprevention$670,480
R01 · FY2009 · CA · contact PI
Translational Research in Colon Cancer Prevention & Treatment$159,773
K05 · FY2009 · CA · contact PI
Polyphenon E for the Chemoprevention of Colorectal Cancer$50,256
R01 · FY2009 · CA · contact PI
Polyphenon E for the Chemoprevention of Colorectal Cancer$635,500
R01 · FY2008 · CA · contact PI
Aberrant Crypt Foci as a Biomarker for Chemoprevention$1
R01 · FY2008 · CA · contact PI
Aberrant Crypt Foci as a Biomarker for Chemoprevention$462,908
R01 · FY2007 · CA · contact PI
Aberrant Crypt Foci as a Biomarker for Chemoprevention$503,681
R01 · FY2006 · CA · contact PI
Clinical Significance of Apoptosis in Colon Cancer$253,773
R01 · FY2006 · CA · contact PI
Clinical Significance of Apoptosis in Colon Cancer$259,880
R01 · FY2005 · CA
Clinical Significance of Apoptosis in Colon Cancer$259,880
R01 · FY2004 · CA
Clinical Significance of Apoptosis in Colon Cancer$259,880
R01 · FY2003 · CA
A THREE ARM PHASE II CHEMOPREVENTION TRIAL IN ADENOMATOU$500,000
N01 · FY2000 · CN